Menstrual and hormonal alterations in juvenile systemic lupus erythematosus

Lupus

Volumn 18, Issue 1, 2009, Pages 38-43

  Medeiros, P B ^a   Febronio M V ^a   Bonfa E ^a   Borba, E F ^a   Takiuti, A D ^a   Silva, C A A ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b not available   (Brazil)

Author keywords

Adolescent; Hormone; Juvenile systemic lupus erythematosus; Menarche; Menstrual Abnormalities

Indexed keywords

CYCLOPHOSPHAMIDE; FOLLITROPIN; IMMUNOSUPPRESSIVE AGENT; LUTEINIZING HORMONE; PROGESTERONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BRAZIL; CASE CONTROL STUDY; CHILD; FEMALE; HUMAN; HYPOPHYSIS DISEASE; MENARCHE; MENSTRUAL CYCLE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; BRAZIL; CASE-CONTROL STUDIES; CHILD; CYCLOPHOSPHAMIDE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUTEINIZING HORMONE; MENARCHE; MENSTRUAL CYCLE; PITUITARY DISEASES; PROGESTERONE; YOUNG ADULT;

EID: 62749186343     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203308094652     Document Type: Article

References (31)

1. Benseler, SM, Silverman, ED. Systemic lupus erythematosus. Pediatr Clin North Am 2005; 52: 443-467.
2. Gurtcheff, S, Hatasaka, H. Fertility and autoimmune disease. In: Lockshin, M, Branch, W, (eds). Handbook of systemic autoimmune disease. Reproductive and hormonal aspects of systemic autoimmune disease, vol. 4. Amsterdam: Elsevier; 2006. p. 29-42.
3. Schaller, J. Lupus in childhood. Clin Rheum Dis 1982; 8: 219-228.
4. Pasoto, SG, Mendonca, BB, Bonfa, E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002; 11: 175-180.
5. Metcalf, MG, Skidmore, D, Lowry, GF, Mackenzie, JA. Incidence of ovulation in the years after the menarche. J Endocrinol 1983; 97: 213-219.
6. Silva, CA, Leal, MM, Simone, VP, et al. Gonadal function in adolescents and young female with systemic lupus erythematosus. Lupus 2002; 11: 419-425.
7. Febronio, MV, Pereira, RM, Bonfa, E, Takiuti, AD, Pereyra, EA, Silva, CA. Inflammatory cervicovaginal cytology is associated with disease activity in juvenile systemic lupus erythematosus. Lupus 2007; 16: 430-435.
8. Gonzalez-Crespo, MR, Gomez-Reino, JJ, Merino, R, et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995; 34: 737-741.
9. Silva, CA, Hilário, MO, Febrônio, MV, et al. Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study. Lupus 2007; 16: 531-536.
10. Hochberg, MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthrits Rheum 1997; 40: 1725.
11. Almeida, PM, Wickerrhauser, H. Critério de classe econômica da Associação Brasileira de Anunciantes (ABA) e Associação Brasileira dos Institutos de Pesquisa de Mercado (ABIPEME); 1991. p. 1-29.
12. Zerwes, EP, Ferreira, C, Zerwes, FP, Horta, BL. Regularidade do ciclo menstrual pós menarche. Rev Bras Ginecol Obstet 1995; 17: 76-78.
13. Huong du, L, Amoura, Z, Duhaut, P, et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84. patients. J Rheumatol 2002; 29: 2571-2576.
14. Brunner, HI, Bishnoi, A, Barron, AC, et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006; 15: 198-206.
15. Marshall, JC, Tanner, JM. Variations in patterns of pubertal changes in boys and girls. Arch Dis Child 1970; 45: 13-23.
16. Gladman, DD, Ibanez, D, Urowitz, MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
17. Brunner, HI, Silverman, ED, To, T, Bombardier, C, Feldman, BM. Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436-444.
18. Lim, GS, Petri, M, Goldman, D. Menstruation and systemic lupus erythematosus (SLE): a case-control study. Arthritis Rheum 1993; 36(Suppl. 5): R23 [abstract].
19. Vogl, D, Falk, W, Dorner, M, Schölmerich, J, Straub, RH. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. J Rheumatol 2003; 30: 269-275.
20. Arnalich, F, Benito, US, Gonzalez, GP, et al. Inadequate production of the progesterone in women with systemic lupus erythematosus. Br J Rheumatol 1992; 31: 247-251.
21. Benito Urbina, S, Harte, LE, Gijon, BJ, Arnalich, FF. Hormonal changes in fertile women with quiescent systemic lupus erythematosus. An Med Interna 1995; 12: 221-224.
22. Bulun, SE, Adashi, EY. The physiology and pathology of the female reproductive axis. In: Larsen, PR, Kronenberg, HM, Melmed, S, Polonsky, KS, (eds), Williams textbook of endocrinology. Philadelphia: Saunders; 2003. p. 587-664.
23. Kim, YK, Wasser, SK, Fujimoto, VY, Klein, NA, Moore, DE, Soules, MR. Utility of follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol and FSH:LH ratio in predicting reproductive age in normal women. Hum Reprod 1997; 12: 1152-1155.
24. de Medeiros, SF, Assi, PE, de Medeiros, MM. Gonadotrophin dynamics during reproductive life. Int J Gynaecol Obstet 2004; 87: 24-28.
25. Soares, PM, Borba, EF, Bonfa, E, Hallak, J, Corrêa, AL, Silva, CA. Gonad evaluation in male systemic lupus erythematosus. Arthritis Rheum 2007; 56: 2352-2361.
26. Medeiros, MM, Silveira, VA, Menezes, AP, Carvalho, RC. Risk factors for ovarian failure in patients with systemic lupus erythematosus. Braz J Med Biol Res 2001; 34: 1561-1568.
27. Boumpas, DT, Austin, HA, Vaughan, EM, Yarboro, CH, Klippel, JH, Balow, JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-369.
28. Wang, CL, Wang, F, Bosco, JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11-14.
29. McDermott, EM, Powell, RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 224-229.
30. Mok, CC, Lau, CS, Wong, RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831-837.
31. Silva, CA, Brunner, HI. Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus. Lupus 2007; 16: 593-599.